merger synergies not fully realized; waiting for better execution.
CVS is a synergy-underperformance watch — the merger synergies with “Etna” haven’t been fully capitalized yet.
The KOL’s base view is that the CVS/“Etna” combination was promising, but actual synergy execution seems incomplete. That keeps CVS in the bullpen until improvements show up over time, with only a small existing position.
"Stocks I Want to Buy! - My Bullpen of Investments"